In one paragraphArticle in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Maria DąbrowskaDepartment of Infectious Diseases and Hepatology, Medical University of Silesia, 40-635 Katowice, Poland.
Jerzy JaroszewiczDepartment of Infectious Diseases and Hepatology, Medical University of Silesia, 40-635 Katowice, Poland.ORCID 0000-0003-0139-4753 Marek SitkoDepartment of Infectious and Tropical Diseases, Jagiellonian University, 30-688 Kraków, Poland.ORCID 0000-0003-3078-8604 Justyna Janocha-LitwinDepartment of Infectious Diseases and Hepatology, Medical University Wroclaw, 51-149 Wroclaw, Poland.ORCID 0000-0002-6072-4559 Dorota Zarębska-MichalukDepartment of Infectious Diseases and Allergology, Jan Kochanowski University, 25-317 Kielce, Poland.ORCID 0000-0003-0938-1084 Ewa JanczewskaDepartment of Basic Medical Sciences, Faculty of Health Sciences, Medical University of Silesia, 41-902 Bytom, Poland.ORCID 0000-0002-5406-4603 Beata LorencPomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdańsk, 80-214 Gdańsk, Poland.ORCID 0000-0002-6319-9278 Magdalena Tudrujek-ZdunekDepartment of Infectious Diseases and Hepatology, Medical University of Lublin, 20-081 Lublin, Poland.ORCID 0000-0002-5640-5432 Anna Parfieniuk-KowerdaDepartment of Infectious Diseases and Hepatology, Medical University of Białystok, 15-569 Białystok, Poland.
Jakub KlapaczyńskiDepartment of Internal Medicine and Hepatology, The National Institute of Medicine of the Ministry of Interior and Administration, 02-507 Warszawa, Poland.
Hanna BerakDaily Department of Hospital for Infectious Diseases in Warsaw, 01-201 Warszawa, Poland.
Łukasz SochaDepartment of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 71-455 Szczecin, Poland.
Beata DobrackaMedicalSpec Medical Center, 53-228 Wrocław, Poland.
Dorota DybowskaDepartment of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland.ORCID 0000-0002-1961-8519 Włodzimierz MazurClinical Department of Infectious Diseases, Specialist Hospital in Chorzów, Medical University of Silesia, 41-500 Katowice, Poland.
Łukasz WażnyDepartment of Infectious Diseases and Hepatology, Medical University of Silesia, 40-635 Katowice, Poland.ORCID 0009-0002-1490-2219 Robert FlisiakDepartment of Infectious Diseases and Hepatology, Medical University of Białystok, 15-569 Białystok, Poland.ORCID 0000-0003-3394-1635 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundOver the past years, the introduction of direct-acting antivirals (DAAs) revolutionized chronic hepatitis C treatment. We aimed to characterize and assess treatment efficacy in three specific groups of patients treated with DAAs: those with active solid malignant tumors (SMTs), hematological diseases (HDs) and hepatocellular carcinomas (HCCs).
methodsA total of 203 patients with active oncological disease (SMT
resultsExtrahepatic symptoms were more frequent in HD patients (17.2% vs. SMT = 10.3%, HCC = 8.2%, without = 7.8%,
conclusionsAs presented in our study, DAA therapy has proven to be highly effective and safe in patients with active SMTs and HDs. However, therapy discontinuations resulting from liver disease progression remain to be the major concern in HCC patients.
Indexed as
direct-acting antiviralshematological diseasehepatitis C virushepatocellular carcinomasolid malignant tumortreatment efficacytreatment safety
Identifiers
PMID39272972
PMCPMC11394372
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390